#United States #Chicago #Caris Life Sciences #Precision Oncology #AACR Annual Meeting

Introduction

Caris Life Sciences®, a trailblazer in next-generation AI TechBio and precision medicine, is set to showcase significant research at the 2025 American Association for Cancer Research (AACR) Annual Meeting. This prestigious event, scheduled from April 25 to April 30 in Chicago, Illinois, presents an impressive selection of 14 abstracts developed in collaboration with the Caris Precision Oncology Alliance™ (POA).

Significance of the Event

The forthcoming AACR meeting serves as a crucial platform for innovation in cancer research. With 14 diverse abstracts spanning across 9 tumor types, Caris aims to underline the vital role of comprehensive molecular profiling in advancing cancer treatment.

As George W. Sledge, Jr., MD, Caris' Executive Vice President and Chief Medical Officer, noted, this year's accepted abstracts exemplify the breadth of cancer research conducted using Caris’ extensive clinic-genomic datasets. The research covers various aspects, including gastro-esophageal, lung, and pancreatic cancers, addressing critical areas in oncology.

Research Highlights

The research presented will include 2 oral presentations and 12 poster presentations. These will emphasize innovative findings and clinical advancements made in partnership with other esteemed cancer centers and institutions.

Minisymposium Presentations

Some key presentations to look forward to include:

• - Pre-operative abemaciclib in localized cisplatin-ineligible MIBC with validation of tissue and ctDNA molecular response (Abstract Number CT127) on April 28
• - Kinase fusion landscape of pancreatic cancer (Abstract Number 3781) on April 28

Poster Presentations

Additionally, attendees can expect to see a range of intriguing poster presentations, such as:

• - The clinical and biological characteristics of gastro-esophageal cancers harboring specific fusions (Poster Number 496/8) on April 27
• - Functional characterization of genomic variants in SMARCA4 (Poster Number 674/7) on April 27
• - Targeting ATM to enhance chemotherapy efficacy in small cell lung cancer (Poster Number LB016/16) on April 27

These exhibits will provide insights into the development of targeted therapies and new biomarkers, showcasing real-world evidence as leveraged by Caris POA collaborators.

Collaboration for Advancements

The Caris POA comprises an impressive network of 96 cancer centers, academic institutions, and healthcare systems, including 47 NCI-designated cancer centers. This collaboration focuses on establishing optimized standards of care in molecular testing, aiming for improved clinical outcomes for cancer patients.

James Hamrick, MD, MPH, Chair of the Caris POA, emphasizes how this partnership empowers clinicians by facilitating significant research advancements. This collaborative effort enhances the understanding of cancer pathogenesis mechanisms, leading to better treatment outcomes.

Conclusion

The 2025 AACR Annual Meeting is set to be a pivotal moment for Caris Life Sciences as they present their innovative research on precision oncology. As they unveil their findings and insights, industry experts and attendees will gain valuable knowledge that could reshape future cancer care.

Following the event, summaries and full abstracts of the research will be made available on Caris' website, underlining their commitment to enhancing precision medicine.

Caris Life Sciences continues to drive forward with innovative solutions aimed at transforming healthcare and promoting improved patient outcomes in the field of oncology.

For more information, visit Caris Life Sciences.